Case description: A 39-year-old Ugandan man was diagnosed HIV-1 positive in 1996 (baseline CD4 count 130/uL, viral load (VL) 235,678 copies/ml), and was commenced on Zidovudine, Lamivudine and Nevirapine therapy. Ten years later the patient presented with sharp, right-sided chest pain. He did not describe any symptoms suggesting infection, nor relating to eyes, skin or joints. Auscultation of the chest was unremarkable. He had tenderness on palpation over the right anterior chest wall. Chest radiograph revealed bilateral hilar lymphadenopathy (BHL). Blood tests showed CD4 count 385 with an undetectable viral load. Full blood count, renal, liver and bone profile were unremarkable. Serum angiotensinconverting enzyme was raised at 119 U/ml (normal range <67 U/ml). Computed tomography of the chest confirmed extensive mediastinal lymphadenopathy, with bilateral hilar, pretracheal, right para-tracheal, pre-aortic and subcarinal nodes involved. The differential diagnoses included tuberculosis and lymphoma. The patient underwent left anterior mediastinoscopy and mediastinal lymph node biopsy. Microbiology cultures of the biopsy were negative and no acid-fast bacilli were seen. Histopathology showed the normal lymph node architecture was effaced by confluent non-necrotising granulomas, with lymphocytes interspersed between the granulomas. There were no micro-organisms on special stains and no evidence of malignancy. The findings were consistent with sarcoidosis. As this patient had BHL only, he did not require steroid treatment, and has remained well. Tuberculosis (TB) is still a major public health problem around world, especially in China, which is the second largest TB patient population in the world. AIDS epidemic have make TB infection more complex than that before, it is especially very difficult to make a diagnosis when an AIDS patient combined with extra-pulmonary TB diseases. Traditional methods for diagnosis of TB infection such as TSTs are not sufficient for confirmation of TB infection in AIDS patients.Here, we use use the recombinant CFP-10 protein as stimulus to detect TB specific T-cell responses in Chinese HIV (+) patients. Methods: CFP-10 was cloned into prokaryotic expression vector pET-32a (+) and transfected into E. coli BL21(DE3) to produce the recombinant CFP-10 protein, and use CFP-10 protein as stimulus to detect specific T-cell responses in HIV(+) persons with or without clinical manifestation of TB diseases. 
OL-041 Apoptosis of CD8+ T-cells in HIV
HIV infected patients with TB diseases (HIV(+)/TB). A1,B1 consisted of cells cultured with fusion protein CFP10 (25 mg/mL); A2,A3 negative controls consisted of cells cultured with medium alone; B2,B3 positive controls consisted of cells cultured with Con A (25 mg/mL).
Results:
The CFP-10 recombinant protein were obtained and purified, In-house ELISPOT IFN-g assay using recombinant CFP-10 antigen show significant high frequencies TB specific T-cell responses in patients of active TB with or without HIV infection. there was 100% consistency to the clinical manifestation, in the HIV(+) group without clinical TB disease, the rate of positive tests results was 24.7%. Our results proved that it is indeed true that some of HIV positive patient have high frequencies of TB specific T-cell responses, it could be used in diagnosis of TB diseases, and it maybe provide a clue to find latent TB infection in Chinese HIV(+) population. The pathogenesis of HPS is presumed to result from an enhanced proinflammatory cytokine secretion and systemic macrophage activation. Previously, we demonstrated that EBV LMP-1 can activate T-cells and upregulate tumor necrosis factor-alpha and interferon-gamma, mediated through the NFkB/ATF5/SAP/ERK signaling, to activate macrophages. Since peroxisome proliferators activated receptor (PPAR) agonists, regulators of cholesterol metabolism, have been shown to exhibit profound effects on the inhibition of proinflammatory cytokines and macrophage activation through NFkB and AP-1 signaling, we adopted a PPAR-g agonist, rosiglitazone, for the potential therapy of HPS using a rabbit model of Herpesvirus papio (HVP, an EBV homologue)-associated HPS. Materials and Results: In vitro, rosiglitazone was shown to inhibit macrophage activation and secretion of tumor necrosis factor-alpha (TNF-a) through inhibition of NFkB signaling in THP1 cell line. Different doses of rosiglitazone were then fed to rabbits after intravenous injection of 5×107 copies of HVP virus at different time courses (7 days and 20 days, respectively) of infection. As compared to the control group which succumbed consistently at around one month, the 4 mg rosiglitazone-treated group showed significant improvement of survival when fed at early stage (7 days) of infection (p < 0.01), while a higher dosage (8 mg) is needed to achieve therapeutic effect at advanced stage (20 days) of infection (p < 0.05). The viral load, TNFa cytokine levels, and laboratory parameters also showed significant improvement in the rosiglitazone-treated group.
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Conclusion: PPAR agonist, in addition to its therapeutic effect for metabolic syndrome, appears to represent a potential regimen of new concept for the control of HPS associated with severe virus infections.
OL-044 HAV seroprevalence among children with 10 24 month ages in Ulaanbaatar The aim of this study was to investigate the prevalence of beta-herpesvirus (HHV-6 and HHV-7) infections among the HIV/AIDS, chronic fatigue sindrome (CFS) patients in comparison with blood donors (BD). Materials and Methods: 52 patients with HIV/AIDS, 49 CFS and 150 healthy BD were enrolled in the study. Active and latent/persistent viral infections determined by nPCR: the presence of viral genomic sequences in PBL DNA only was defined as latent/persistent infection; sequences in PBL DNA and blood plasma DNA was defined as active infection. Concurrent infection with both HHV-6 and HHV-7 was defined as simultaneous presence of both virus genomic sequences in DNA sample of patient (isolated from PBL or blood plasma).
Results: PCR analysis did not reveal a significant diference in the prevalence of latent/persistent HHV-7 infection
